Close
CDMO Safety Testing 2026
Novotech

Anacor develops first candidate under Lilly pact

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...
- Advertisement -

Anacor Pharmaceuticals has developed the first candidate under its animal health research agreement with Eli Lilly.Under the contract, the companies will explore the usage of Anacor’s boron chemistry to discover products for a variety of animal health applications. The research is funded by Eli Lilly which is also responsible for future development and commercialization of the products that will be developed under this deal.The tie up allows Anacor to get around $1m payment for reaching milestone.Eli Lilly is also responsible to pay additional development and regulatory milestones to Anacor including tiered royalties from the high single digits to low double digits on future sales.

Latest stories

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...

AstraZeneca UK Investment Resumes with ยฃ300m Commitment

In a reversal of its earlier stance, AstraZeneca has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป